QC
CADL icon

Quadrature Capital’s Candel Therapeutics CADL Stock Holding History

Quadrature Capital’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Sell
18,178
-2,845
-14% -$21.5K ﹤0.01% 1370
2026
Q1 		$103K Buy
+21,023
New +$114K ﹤0.01% 1222
2025
Q4 		– Sell
-13,831
Closed -$70.5K – 1284
2025
Q3 		$70.5K Buy
+13,831
New +$79.9K ﹤0.01% 926

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Quadrature Capital's CADL Position: Q2 2026 in Review

Quadrature Capital reduced its Candel Therapeutics (CADL) stake by 14% in Q2 2026, selling an estimated $21.5K and leaving 18,178 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Quadrature Capital first reported a position in CADL in Q3 2025 and has held it in 3 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Quadrature Capital held 18,178 shares of Candel Therapeutics worth $187K as of Q2 2026.
  • Quadrature Capital sold 2,845 Candel Therapeutics shares in Q2 2026, an estimated $21.5K.
  • Candel Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1370 holding.
  • Quadrature Capital first reported a position in Candel Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.